Antibody Information

General Information of This Antibody

Antibody ID	ANI0YWMXN
Antibody Name	Thio hu anti-Her2 7C2 HC A140C
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

WO2017214024A1 ADC-106 [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 28.32% (Day 17)	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm³, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0. Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 48.87% (Day 17)	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm³, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0. Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

References

Ref 1	Silvestrol antibody-drug conjugates and methods of use; 2017-12-14.